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The authors retrospectively reviewed the cytological slides of 44 histopatholo-
gically confirmed fibroepithelial lesions of the breast, of which 11 were fibroad-
enoma (FA), 19 benign phyllodes tumours (PTLGM), 8 borderline (PTBM) and 6
malignant (PTHGM). The 2 FA misdiagnosed as PTLGM in cytological smears
were both of cellular type. NORS were quantified in a series of the above cases
using the silver-colloid method. Expression of Ki-67 and PCNA were evaluated
by immunohistochemistry on sections from the corresponding paraffin blocks.
The results were compared with morphological parameters.
In phyllodes tumours (PT), the AgNOR scores showed a tendency to increase
with degrees of malignancy. There was significant correlation between Ag-
NOR counts and proliferation rates as determined by Ki-67 and PCNA immu-
nostaining. Ki-67 and PCNA expression correlated with mitotic count, stromal
overgrowth, cellularity and atypia in PT. Determination of the AgNOR number
per cell revealed an overlap between FA and PTLGM. The proliferating activity
determined by immunohistochemistry with Ki-67 and PCNA antibodies did not
reveal any significant difference between FA and PTLGM.
In summary, Ki-67 and PCNA expression is suggested as a marker of stromal
element proliferation. The results obtained confirm the diagnostic difficulties in
distinguishing PTLGM from FA of the cellular type using fine needle aspiration
cytology.
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INTRODUCTION
Fibroepithelial tumours of the breast include fi-
broadenoma and phyllodes tumours. These are bi-
phasic lesions, whose biology is mainly determined
by the stromal element. FA is benign neoplasm. Phyl-
lodes tumours are well known for their unpredict-
able behaviour [4, 7]. Previous studies have empha-
sised that several characteristics of the stromal com-
ponent in PT must be considered together in assess-
ing their malignant potential [7]. In addition to con-
ventional pathological parameters, several methods,
including the determination of proliferative activity,
provide information concerning the biological be-
haviour and clinical outcome of these neoplasms [8].
Proliferative activity can be determined by different
immunohistochemical markers, such as Ki-67 and
PCNA or by quantitative analysis of AgNORs [2]. Some
investigators have tried to prove the usefulness of
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such determination in differential diagnoses of be-
nign and malignant lesions of the breast [2]. With
regard to fibroepithelial tumours it is extremely im-
portant to establish the correct diagnosis from the
therapeutic point of view [6].
The aim of our study was the evaluation of AgNOR,
KI-67 and PCNA expression in fibroepithelial tumours
of the breast in correlation with morphological pa-
rameters.
MATERIAL AND METHODS
Cytological slides and formalin-fixed, paraffin-
embedded tissues from 44 fibroepithelial tumours
of the breast diagnosed in the Centre for Oncology
in Białystok were retrospectively reviewed. These in-
cluded 11 fibroadenomas (FA), 19 benign phyllodes
tumours (TLGM), 8 borderline phyllodes tumours
(PTBM) and 6 high-grade malignant phyllodes tu-
mours (PTHGM). These were histologically classified,
taking into account mitotic activity, atypia, stromal
overgrowth and cellularity, using a scale of 1–3. The
cytological material, obtained by FNAB, was routinely
stained with HE, destained and then stained again
using the silver-colloid method to visualise NORs.
Mean AgNOR count was evaluated in each case in
100 randomly chosen nuclei. Expressions of Ki-67
and PCNA were evaluated by immunohistochemis-
try on sections from the corresponding paraffin
blocks. Immunostaining was performed with mon-
oclonal antibodies PCNA (PC-10, Dako) and Ki-67
(Ki-67, Dako) using a LSAB KIT with DAB as a chro-
mogen. The percentages of cells expressing Ki-67 and
PCNA were determined by counting 500 stromal cells
per slide. The percentage of positive nuclei was ex-
pressed as the labelling index (LI). The significance of
the differences in scores between all the groups was
assessed using the chi-squared and Mann-Whitney test.
The correlation between the scores and counts and
pathological variables was evaluated using Pearson and
Spermans correlation analysis. Values of p £ 0.05 were
considered as statistically significant.
RESULTS AND DISCUSSION
Fine needle aspiration cytology, now an integral
part of the pre-operative investigation of breast le-
sions, does not always precisely define the character
of a fibroephitelial tumour. In our series the initial
cytological diagnosis was confirmed histopatholog-
ically, although there were some difficulties in cor-
rect qualification of the lesion. The 2 FA misdiag-
nosed as PTLGM in cytological smears were FA of
the cellular type. Determination of the AgNOR num-
ber per cell revealed an overlap between FA and
PTLGM. Proliferating activity determined by immu-
nohistochemistry with Ki-67 and PCNA antibodies
did not reveal any significant difference between the
lesions. Krishnamurthy et al. [5] distinguish both neo-
plasms in H-E slides based on a proportion of long,
short, round and oval nuclei. The presence of long
nuclei above 30% qualifies the lesion to the PT group.
The lesions with 10–30% long nuclei should be cat-
egorised as indeterminate. The stromal cellularity of
some FA may overlap with that of benign PT. Immu-
nohistochemical evaluation of proliferating activity
using Ki-67 antibodies performed by Kaya et al. [3]
revealed no significant difference between FA of the
cellular type and PTLGM. Hasebe et al. [1] noted
a significant relationship between proliferating ac-
tivity and stromal cellularity regulated by fibroblast
growth factor and fibroblast growth factor recep-
tor. Expression of the factors examined was higher
in FA of the cellular type in comparison with FA of
the conventional type. The above data may explain
the diagnostic difficulties in distinguishing PTLGM
from FA of the cellular type using FNA. In the series
of PT examined the mean number of AgNOR dots
per nucleus was 1.38; 1.94; 3.18; 4.98 in FA, PTLGM,
PTBM and PTHGM respectively. Mean Ki-67 — LI was
1.98; 2.91; 2.13; 7.63 in FA, PTLGM, PTBM and PTH-
GM respectively. Mean PCNA LI was 3.93; 5.94;
31.78; 83.87 in FA, PTLGM, PTBM and PTHGM re-
spectively. The AgNOR values showed a tendency to
increase with higher degrees of malignancy. There
was a significant correlation between AgNOR counts
and proliferation rates as determined by Ki-67 and
PCNA immunostaining. Ki-67 and PCNA expression
correlated significantly with mitotic counts, stromal
overgrowth, cellularity and atypia. Our results are in
agreement with others [8] and prove Ki-67 and PCNA
antigens to be useful in the analysis of stromal pro-
liferation in phyllodes tumours.
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